Inventor · disambiguated record
Stefan Woll
Also filed as: WOLL STEFAN · WÖLL STEFAN
19 granted patents·7 pending applications·75 citations·filing 2010–2024
93Inventor score
Top patents by PatentIndex Score
26 records- 0193US11859008B2Antibodies for treatment of cancer expressing claudin 6GANYMED PHARMACEUTICALS GMBH·Filed 2020·Granted Jan 2, 2024·2 cites·12 claims
- 0292US9487584B2Antibodies specific for claudin 6 (CLDN6)SAHIN UGUR·Filed 2010·Granted Nov 8, 2016·19 cites·20 claims
- 0392US9321842B2Antibodies for treatment of cancerSAHIN UGUR·Filed 2012·Granted Apr 26, 2016·14 cites·30 claims
- 0490US10233253B2Antibodies for treatment of cancer expressing claudin 6GANYMED PHARMACEUTICALS AG·Filed 2016·Granted Mar 19, 2019·7 cites·16 claims
- 0590US9770487B2Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic adenocarcinomaGANYMED PHARMACEUTICALS AG·Filed 2014·Granted Sep 26, 2017·11 cites·30 claims
- 0689US10053512B2Antibodies against claudin 18.2 useful in cancer diagnosisGANYMED PHARMACEUTICALS AG·Filed 2016·Granted Aug 21, 2018·6 cites·34 claims
- 0789US9512232B2Antibodies against Claudin 18.2 useful in cancer diagnosisGANYMED PHARMACEUTICALS AG·Filed 2013·Granted Dec 6, 2016·9 cites·11 claims
- 0888US10314890B2Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic cancerGANYMED PHARMACEUTICALS AG·Filed 2017·Granted Jun 11, 2019·5 cites·40 claims
- 0987US2024309108A1Antibodies against claudin 18.2 useful in cancer diagnosisASTELLAS PHARMA INC·Filed 2024·Application pending·0 cites
- 1085US2024092896A1Antibodies specific for claudin 6 (cldn6)GANYMED PHARMACEUTICALS GMBH·Filed 2023·Application pending·0 cites
- 1184US11473085B2Methods and compositions for diagnosis and treatment of cancerGANYMED PHARMACEUTICALS AG·Filed 2019·Granted Oct 18, 2022·1 cites·10 claims
- 1284US2024101703A1Antibodies for treatment of cancer expressing claudin 6GANYMED PHARMACEUTICALS GMBH·Filed 2023·Application pending·0 cites
- 1383US2024209079A1Antibodies useful in cancer diagnosisASTELLAS PHARMA INC·Filed 2024·Application pending·0 cites
- 1481US2024091312A1Combination therapy involving antibodies against claudin 18.2 for treatment of cancerASTELLAS PHARMA INC·Filed 2023·Application pending·0 cites
- 1578US11919951B2Antibodies useful in cancer diagnosisASTELLAS PHARMA INC·Filed 2022·Granted Mar 5, 2024·0 cites·21 claims
- 1677US2023193261A1Methods and compositions for diagnosis and treatment of cancerGANYMED PHARMACEUTICALS GMBH·Filed 2022·Application pending·0 cites
- 1775US9932401B2Antibodies specific for claudin 6 (CLDN6)GANYMED PHARMACEUTICALS AG·Filed 2016·Granted Apr 3, 2018·1 cites·19 claims
- 1873US11826402B2Combination therapy involving antibodies against claudin 18.2 for treatment of metastatic pancreatic adenocarcinomaASTELLAS PHARMA INC·Filed 2020·Granted Nov 28, 2023·0 cites·7 claims
- 1971US11858988B2Antibodies specific for claudin 6 (CLDN6)GANYMED PHARMACEUTICALS GMBH·Filed 2020·Granted Jan 2, 2024·0 cites·24 claims
- 2071US10946069B2Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic cancerASTELLAS PHARMA INC·Filed 2019·Granted Mar 16, 2021·0 cites·20 claims
- 2170US11976130B2Antibodies against claudin 18.2 useful in cancer diagnosisGANYMED PHARMACEUTICALS AG·Filed 2018·Granted May 7, 2024·0 cites·16 claims
- 2268US11279757B2Antibodies useful in cancer diagnosisASTELLAS PHARMA INC·Filed 2018·Granted Mar 22, 2022·0 cites·20 claims
- 2368US10919974B2Antibodies for treatment of cancer expressing claudin 6GANYMED PHARMACEUTICALS AG·Filed 2018·Granted Feb 16, 2021·0 cites·12 claims
- 2466US10745477B2Antibodies specific for claudin 6 (CLDN6)GANYMED PHARMACEUTICALS AG·Filed 2018·Granted Aug 18, 2020·0 cites·19 claims
- 2556US2018119146A1Methods and compositions for diagnosis and treatment of cancerGANYMED PHARMACEUTICALS AG·Filed 2017·Application pending·0 cites
- 2650US9809815B2Methods and compositions for diagnosis and treatment of cancerSAHIN UGUR·Filed 2010·Granted Nov 7, 2017·0 cites·13 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →